Oda N, Yamashita N, Minoguchi K, Takeno M, Kaneko S, Sakane T, Adachi M
First Department of Internal Medicine, Showa University, Tokyo, Japan.
Cell Immunol. 1998 Nov 25;190(1):43-50. doi: 10.1006/cimm.1998.1391.
Rush immunotherapy (RI), a modified allergen-specific immunotherapeutic procedure, is an effective treatment for extrinsic (atopic) asthma, although the precise mechanism of its action is unclear. We have thus investigated the effect of RI on T cell response in seven mite-allergen-sensitive asthmatic patients who were successfully treated with RI. The proliferative response to mite allergen profoundly decreased after 3 months of therapy compared to the response before therapy; the response, however, recovered 18 months after RI. Regarding cytokine production patterns of mite-specific T cells, RI brought about a shift in cytokine profiles from Th2 to Th0 or Th1 in mite-specific T cell clones. The data indicate that the efficacy of RI is due to modification of T cell responses to mite antigens. Allergen RI results in the conversion of Th2 to Th1 and Th0 cells and/or selection of Th1 and Th0 cells over Th2 cells and thus may improve both clinical symptoms and airway inflammation in asthmatics.
快速免疫疗法（RI）是一种改良的变应原特异性免疫治疗方法，是治疗外源性（特应性）哮喘的有效手段，尽管其确切作用机制尚不清楚。我们因此研究了快速免疫疗法对7例成功接受该疗法治疗的尘螨变应原敏感哮喘患者T细胞反应的影响。与治疗前相比，治疗3个月后对尘螨变应原的增殖反应显著降低；然而，快速免疫疗法18个月后反应恢复。关于尘螨特异性T细胞的细胞因子产生模式，快速免疫疗法使尘螨特异性T细胞克隆中的细胞因子谱从Th2转变为Th0或Th1。数据表明，快速免疫疗法的疗效归因于T细胞对尘螨抗原反应的改变。变应原快速免疫疗法导致Th2细胞向Th1和Th0细胞转化和/或Th1和Th0细胞相对于Th2细胞的选择，因此可能改善哮喘患者的临床症状和气道炎症。
